In this episode Mike Ward, Clarivate’s Head of Thought Leadership for Life sciences and healthcare, spoke to Johnny Ohlson, Founder of Touchlight, a company who has developed a novel synthetic DNA vector. In recent years, we've seen that by harnessing the power of DNA, it has been possible to achieve success in treating previously incurable hereditary diseases and even tackle major pandemics. However, whether the answer is cell or gene therapies or RNA vaccines, one thing they all have in common is that they require DNA in some form or another as the starting material. Through Touchlight, Johnny Ohlson and his talented team have built a business that can make DNA at unprecedented speed, scale and purity. Johnny, a serial entrepreneur not originally from a biopharma background, shares with us his story of breaking successfully into a complex industry. This podcast demonstrates that innovation at its heart is more about a combination of vision, relationships and talented people rather than prior experience.
Hosted on Acast. See acast.com/privacy for more information.
